Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) (2017) Loibl S, De La Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, et al. Journal article Adjvant HIPEC in gastric cancer patients with high risk of peritoneal carcinomatosis (2017) Aladashvili A, Croner R, Pantsulaia I Conference contribution Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma (2017) Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, et al. Journal article Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition (2017) Heppt MV, Heinzerling L, Kaehler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, et al. Journal article Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma (2017) Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, Kaehler KC, et al. Journal article Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity (2017) Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, et al. Journal article Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG) (2017) Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, Sommer M, et al. Journal article Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation (2016) Tinhofer I, Budach V, Saki M, Konschak R, Niehr F, Joehrens K, Weichert W, et al. Journal article Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) (2016) Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, et al. Conference contribution Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29) (2016) Von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, Hilfrich J, et al. Journal article